People · Operator
Named in public records as an officer, director or promoter · active 2022–2025 · Biotechnology, Other Health Care, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Biolinq Inc | — | Biotechnology | Series C | $247.4M | $619.1M | 2023 |
| Imbria Pharmaceuticals, Inc. | — | Biotechnology | Series C | $140.2M | $406.0M | 2025 |
| Eyenuk, Inc. | — | Other Health Care | Series B | $28.3M | $262.8M | 2022 |
| Axena Health, Inc. | — | Healthtech | Series B | $26.8M | $288.0M | 2023 |
Zina Affas Besse at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Zina Affas Besse on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Daniel Bradbury | 1 | 7 |
| Nancy Hong | 1 | 4 |
| Eileen Maus | 1 | 3 |
| Rebecca Luse | 1 | 3 |
| Dan Bradbury | 1 | 3 |
| Shacey Petrovic | 1 | 3 |
| Jim O'Connor | 1 | 3 |
| CHRIS DIMITROPOULOS | 1 | 3 |
| Lana Ghanem | 1 | 2 |
| Robert Binney | 1 | 2 |
| Jonathan Dean | 1 | 2 |
| Martin Coyne | 1 | 2 |
| Manish Potti | 1 | 2 |
| Charles Dunn | 1 | 2 |
| RICHARD YANG | 1 | 2 |
| Ken Horne | 1 | 2 |
| DAVID AFFAS ARIDA | 1 | 1 |
| DAVID ARIDA | 1 | 1 |
| Edward Kliphuis | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.